Simon Heeke

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

Carl M. Gay, C. Allison Stewart, Elizabeth M. Park et al. · Cancer Cell · 2021 · 864 citations · Full text

Immunogenetics, Systems Biology, Distinct Therapeutic Vulnerabilities +11

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne Robichaux, Xiuning Le, R.S.K. Vijayan et al. · Nature · 2021 · 416 citations · Full text

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

James Chih‐Hsin Yang, Martin Schüler, Sanjay Popat et al. · Journal of Thoracic Oncology · 2020 · 268 citations · Full text

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

Yasir Y. Elamin, Jacqulyne Robichaux, Brett W. Carter et al. · Cancer Cell · 2022 · 102 citations · Full text

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Monique B. Nilsson, Yan Yang, Simon Heeke et al. · Cancer Cell · 2023 · 90 citations · Full text

Radiation Oncology, Signaling Pathway, Receptor Tyrosine Kinase +7